



## EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD

**MINUTES OF THE MEETING HELD ON WEDNESDAY 21st JUNE 2017 AT  
12.30pm**

**IN SEMINAR ROOM 6, LEARNING & DEVELOPMENT CENTRE,  
ROYAL BLACKBURN HOSPITAL**

### **PRESENT:**

Dr D Gavan (DG)	Consultant Radiologist ELHT (Chairperson)
Dr L Rogan (LR)	Head of Medicines Commissioning NHS EL CCG
Dr S Jackson (SJ)	Clinical Commissioning Group MM Lead, GP EL
Mrs C Dugdale (CD)	Meds Management Pharmacist NHS BwD CCG
Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
Mr J Vaughan (JV)	Commissioning Support Pharmacist NHS EL/BwD
Dr S Preeti (SP)	GP, BwD CCG
Dr K Burch (KB)	Consultant Microbiologist ELHT

### **In Attendance**

Ms L Prince	Medicines Management Technician EL CCG
-------------	--

### **2017/068: APOLOGIES:**

Mrs C Woffindin (CW)	Medicines Information Manager, ELHT
Dr Y Naheed	GP, EL CCG
Dr S Davies (SD)	GP, EL CCG
Mrs L Holden (LH)	Pharmacist LCFT (representing Ms S Ramdour)
Dr T McKenzie (TM)	GP, EL CCG
Mr N Fletcher (NF)	Director of Pharmacy ELHT
Mr A Gray (AG)	Clinical Pharmacist, ELHT

### **2017/069: DECLARATION OF INTEREST**

None declared – relevant to agenda items.

### **2017/070: MINUTES OF APRIL MEETING:**

Accepted as a correct record.

### **2017/071: MATTERS ARISING:**

**2017/007: Formulary Updates – Sodium valproate** – nothing received from LCFT, with no response from David Jones. Deadline for implementation is October 2017. LR to raise through LMMG.

**2017/041: Tolvaptan/Demeclocycline for Hyponatraemia** –VG has raised with endocrinology who suggested more likely to be used by oncology. Need to approach NHSE to discuss re-charge. Prescribing in primary care is historic and patients will be referred back to secondary care. CCG's to initiate searches to find patients for referral.

**2017/061: LMMG Consultations: Psoriasis Primary Care Guideline – Formulary** to be reviewed in line with guideline.

### **2017/072: NEW PRODUCT REQUEST – Afrezza – Inhaled insulin**

Request made by Dr Jostle for one specific patient who has needle phobia and numerous admissions due to uncontrolled condition. This will be managed through the hospital and VG will speak to directorate to agree the mechanism. Acknowledged by ELMMB as an exception for unique patient. The product will not be added to formulary nor passed out to primary care.

**Resolved: Afrezza not be included on formulary, but acknowledged for use as an exception for this patient.**

### **2017/073: NEW PRODUCT REQUEST – Temocillin (Negaban®)**

Antimicrobial shortages and a growing problem with multi drug resistant gram negative bacteria are resulting in limited options for treating certain infections., The addition of Temocillin will give an additional option in more resistant organisms. PHE and Scottish guidelines have suggested Temocillin as an alternative, although it is more expensive than tazosin. Its use will be in urosepsis where gentamicin can't be given and upon advice of consultant microbiologist for resistant gram negative organisms.

**Resolved: Temocillin will be added to formulary & secondary care Microguide**  
**Traffic Light: RED**

### **2017/074: LMMG CONSULTATIONS (for June LMMG)**

For information only - comments already sent.

**Nicotine Replacement Therapy Position Statement Reviewed** – noted that the statement could cause confusion. ELHT give a limited supply on discharge when the patient is referring into a stop smoking service. There are currently issues with waiting lists. ELHE local policy to be amended. JV to review.

**Generic Biosimilars Statement** – updated

### **2017/075: LMMG CONSULTATIONS (for July)**

**Liraglutide (Saxenda®) for Weight Management recommendation** – recommended as BLACK Traffic Light due to insufficient clinical evidence to support its use. ELHT no comments to feed back.

**Budesonide (Cortiment) Recommendation** – comments received from Dr Collum agreed that this would be used for a very select group of patients for an 8 week period. RED Traffic Light recommendation agreed as appropriate.

**Oral Nutritional Supplements in Primary Care Guidance** – comments suggested a more localised agreement/document was required. Work has already been initiated across Pennine Lancashire with an initial focus on care homes and food fortification.

**Mycophenolate Shared care Guidelines** - update to include unlicensed indications.

**Palliative Care Guidelines** – Consensus approach – LR met with hospital pharmacist regarding alignment of palliative care drugs in community pharmacy. Proposal to add Glycopyrronium injection and Dexamethasone injection to the formulary and remove metoclopramide.

**Resolved: JV/LR to send responses to LMMG.**

## **2017/076 LMMG RECOMMENDATIONS (from April LMMG)**

### **Pitolisant Recommendation**

Original recommendation was BLACK Traffic Light. Following further review based on new evidence recommendation was agreed as written for ELHE. **Traffic Light: BLACK**

### **Empagliflozin Position Statement**

The recommendation was agreed as written for ELHE. **Traffic Light: GREEN**

### **Rheumatoid Arthritis Biologics Pathway – updated**

Acknowledged by ELMMB as latest version.

## **2017/077 LMMG RECOMMENDATIONS (from May LMMG)**

### **Ferric maltol (Ferracru®) recommendation**

The recommendation was agreed as written for ELHE. **Traffic Light: BLACK**

### **Psoriasis in Primary Care Guideline**

Acknowledged by ELMMB. Formulary products to be aligned and updated in line with the guidance and brought back to July meeting for information.

### **Home Monitoring of Blood Glucose Levels Guideline**

Agreed that local guideline more appropriate. LMMG guideline not approved for use in ELHE.

## **2017/078: FORMULARY UPDATES**

**Glycopyrronium Liquid** – tablets currently on formulary for off-licence use. There is now a liquid available that is more cost effective – Colonis Pharma Glycopyrronium liquid 1mg/5mL. To remove tablets from formulary and add Colonis Pharma Glycopyrronium liquid 1mg/5mL to be prescribed by brand.

**Traffic Light: AMBER**

**Optilube Active Sterile Lubricating Jelly** – add to formulary. **Traffic Light: GREEN**

**Fentanyl patches** – add Matrifen® patches to formulary. **Traffic Light: GREEN**

**Morphine SR oral** – add MST® tablets to formulary **Traffic Light: GREEN**

**Imipramine** – for depression and/or neuropathic pain assign BLACK traffic light. All patients to be reviewed. **Traffic Light: BLACK**

**Trimipramine** - for depression and/or neuropathic pain assign BLACK traffic light. All patients to be reviewed. **Traffic Light: BLACK**

**Nortriptyline** - for depression and/or neuropathic pain assign BLACK traffic light. All patients to be reviewed. **Traffic Light: BLACK**

**Lanthanum** – should be commissioned through NHSE for dialysis patients. Patients to be repatriated. Change from Amber to RED Traffic light **Traffic Light: RED**

**Liothyronine sodium monotherapy** – clarification required regarding traffic light status for both mono and add-on therapy. It is Black traffic light for both. **Traffic Light: BLACK**

**Molludab®** (potassium hydroxide topical) not recommended for treatment of molluscum contagiosum. **Traffic Light: BLACK**

**Retigabine** – remove from formulary, item withdrawn by manufacturer

**Pivmecillinam** – Alternative when nitrofurantoin is contra-indicated. Currently AMBER To be brought to next meeting for discussion.

#### **May Updates to Website**

The following items are to be removed from formulary:

**Gentamicin Sponge** (Collatamp G®) - discontinued

**Rose Bengal 1% Eye Drops** (Minims®Rose Bengal) - discontinued

**Dequalinium Chloride & Benzacaine Lozenges** (Dequacaine®) - discontinued

**Dolasetron 12.5mg in 0.625ml Injection** – no longer used

**Hexastarch Infusion** (eloHAES®) – no longer used

**Hydrocortisone & Clioquinol Cream/Ointment** (Vioform-HC®) - discontinued

**Neomycin & Hydrocortisone Eye drops** (Neo-Cortef®) - discontinued

**Phenothrin 0.2% Alcoholic Lotion/Liquid** (Full Marks) - discontinued

**Roc Sante Soleil® UVB-SPF 25** - discontinued

#### **Other updates**

**Quetiapine m/r tablets** to be prescribed by brand. Remove Ebesque XL from formulary as discontinued and add Sondate XL. **Traffic Light: GREEN**

**Buprenorphine transdermal weekly patches** – add Butec® and Sevodyne® as preferred brands for new patients as more cost-effective. Remove Butrans® from formulary. **Traffic Light: GREEN**

**Buprenorphine transdermal 96 hourly patches - Transtec®** - add Bupeaze® as preferred brand for new patients as more cost-effective. **Traffic Light: GREEN**

**Carbocisteine Oral Solution 250mg/5mL** – add to formulary for paediatric use only **Traffic Light: RED**

**Ethinylestradiol 30mcg/ drospirenone 3mg (Yacella)** – add branded generics to formulary – Yiznell®, Lucette® **Traffic Light: GREEN**

**Botulinum Toxin** for Hyperhidrosis associated with social anxiety (botox) – not recommended by NICE CG159. **Traffic Light: BLACK**

**Salmeterol/fluticasone propionate** (MDI & DPI) – AirFluSal® DPI and AirFluSal® MDI added to formulary as preferred choice where Fostair® and Duoresp® are not suitable and patient's wishes to remain on fluticasone. **Traffic Light: GREEN**

#### **June updates to website**

**TEE2 meter** – add to formulary as 1<sup>st</sup> line choice for ALL Type 2 diabetic patients.

**Contour Next meter** – available for Type 1 diabetics and patients with low haematocrit levels.

**Note:** VG to liaise with specialist service to ensure any inaccuracies with equipment are reported to the MHRA.

**Ondansetron tablets** – currently RED traffic light – agreed to switch to GREEN Traffic Light for all conditions, including hyperemesis (off licence use) **Traffic Light: GREEN**

**Trazodone Liquid 50mg/5mL** – BwD and EL CCG's have been identified through the National Rightcare Programmes as significant outliers in the use of this formulation (used off-licence). ELMMB agreed to assign RED Traffic Light for use only in exceptional cases. **Traffic Light: RED**

**Spironolactone suspension and solution 250mg/5mL, 50mg/5mL, 5mg/5mL, 100mg/5mL** - currently AMBER on formulary and mainly used in paediatrics. Agreed to assign RED traffic light to minimise risk of potential prescribing, transcribing and dispensing errors. **Traffic Light: RED**

**Chlorothiazide suspension 250mg/5mL, 25mg/5mL** - currently AMBER on formulary and mainly used in paediatrics. Agreed to assign RED traffic light to minimise risk of potential prescribing, transcribing and dispensing errors. **Traffic Light: RED**

**Sodium bicarbonate oral solution and Sodium chloride oral solution** – branded products are now available which are more cost effective. Agreed to add to formulary as follows:

**Sodium Bicarbonate Solution – SodiBic® 1mmol/1mL (Arjun) Traffic Light: AMBER**  
**Sodium Chloride Solution – SodiClor® 5mmol/1mL (Arjun) Traffic Light: AMBER**

**Melatonin** – no changes to be made. Melatonin to be tabled again at a future meeting

#### **2017/079: ELHE: GUIDELINES FOR THE MANAGEMENT OF COPD ELHE: COPD RESCUE PACK INFORMATION**

Guidelines updated in line with GOLD Assessment Guideline 2017. Concerns raised by KB that the guidelines promotes the use of antibiotics and are not reflective of NICE guidance. Suggestion that the wording needs amending in line with NICE exacerbation guidance. JV to review guidance and bring back to July meeting.

## **2017/080: ELCCG: FOOD FIRST RESOURCES**

Food First Resources for care homes to support Oral Nutritional Supplements Position Statement.

**Resolved:** Food First Resources acknowledged by ELMMB

## **2017/081: ELMs REPRESENTATIVE**

LR explained that ELMs had requested the opportunity to attend future meetings. ELMMB agreed they could attend for information.

**Resolved:** LR to inform ELMs of the outcome.

## **2017/082: NICE RECOMMENDATIONS (from April)**

Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine (TAG 440) not recommended by NICE. **Traffic Light: BLACK**

Daclizumab for treating relapsing–remitting multiple sclerosis (TAG 441) recommended as an option by NICE. Approved in line with NICE. **Traffic Light: RED**

Ixekizumab for treating moderate to severe plaque psoriasis (TAG 442) recommended as an option by NICE. Approved in line with NICE. **Traffic Light: RED**

Obeticholic acid for treating primary biliary cholangitis (TAG 443) recommended as an option by NICE. Approved in line with NICE. **Traffic Light: RED**

## **2017/083: NICE RECOMMENDATIONS (from May)**

Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) (TAG 444) **Traffic Light: BLACK**

Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (TAG 445) recommended as an option by NICE. Approved in line with NICE. **Traffic Light: RED**

## **2107/084 EAMS:**

### **Glecaprevir/Pibrentasvir for chronic Hepatitis C**

Acknowledged by ELMMB.

**Traffic Light: RED**

### **Oxervate for treatment of moderate to severe neurotrophic keratitis**

Acknowledged by ELMMB.

**Traffic Light: RED**

## **Any other Business:**

### **Research policy**

Although The Research Policy covers R&D in the broader sense, members agreed that only projects that involved medicines directly or could have an impact on prescribing and medicines would go through the ELMMB for discussion and recommendations. Research outside of this scope would be managed through a separate mechanism.

**Resolved:** Research related to medicines will initially come to ELMMB for discussion. Other research projects will require a separate panel/group.

## **STANDING ITEMS**

### **2017/085: FOR ACTION/INFORMATION: LANCASHIRE MEDICINES MANAGEMENT GROUP MINUTES – April 2017**

Minutes acknowledged

### **2017/086: FOR ACTION/INFORMATION: ANTIMICROBIAL STEWARDSHIP COMMITTEE MINUTES – Jan 2017**

Minutes acknowledged

### **2017/087: FOR ACTION/INFORMATION: ANTIMICROBIAL STEWARDSHIP COMMITTEE MINUTES – Mar 2017**

Minutes acknowledged

### **2017/088: FOR ACTION/INFORMATION: LANCASHIRE MEDICINES MANAGEMENT GROUP MINUTES - May 2017**

Minutes acknowledged

### **2017/089: FOR ACTION/INFORMATION: LANCASHIRE CARE FOUNDATION TRUST D & T MINUTES- May 2017**

Minutes acknowledged

**DATE OF NEXT MEETING** – Next meeting is **Wednesday 19<sup>th</sup> July 2017 12.30pm**, Seminar Room 8, Learning and Development Centre, RBH.

**ACTION SHEET FROM  
EAST LANCASHIRE HEALTH ECONOMY  
MEDICINES MANAGEMENT BOARD**

**WEDNESDAY 21<sup>st</sup> JUNE 2017**

<b>MINUTE NUMBER</b>	<b>DESCRIPTION</b>	<b>ACTION</b>	<b>DATE</b>
<b>2017/007</b>	<b>Formulary Updates – Sodium valproate</b> – ask LCFT to consider all patients to be referred back. LMMG pursuing with LTHT	LH LR	Apr 17 Apr 17
<b>2017/041</b>	<b>Tolvaptan/Demeclocycline for Hyponatraemia</b> – endocrinologist to be asked to review	VG	May 17
<b>2017/061:</b>	<b>LMMG Consultations: Psoriasis Primary Care Guideline</b> – To review products in line with formulary and discuss with Integrated Dermatology Service.	JV	May 17
<b>2017/074</b>	<b>LMMG Consultations (for June)</b> Nicotine Replacement Therapy Position Statement - Review	JV	July 17
<b>2017/077</b>	<b>LMMG Recommendations (from May LMMG)</b> <b>Psoriasis Primary Care Guideline</b> – update formulary section in line with guideline (linked with 2017/061)	JV	July 17
<b>2017/078</b>	<b>Formulary Updates –</b> Pivmecillinam – discuss formulary status at next meeting		July
<b>2017/079</b>	<b>ELHE: Guidelines for the Management of COPD</b> <b>ELHE: COPD Rescue Pack Information</b> – to review guideline wording.	JV	July 17